

# NEWS RELEASE

---

Date: 8-08-15  
FOR IMMEDIATE RELEASE

## **FDA Approves new technology for Senza Spinal Cord Stimulation System**

Dr. Shawn Sills will be the first in the State of Oregon to use this new technology in procedures since the SCS system received FDA approval on 05-08-2015.

The FDA announced the approval the first implantable spinal cord stimulation (SCS) system to treat chronic back pain using high frequency (up to 10,000 Hz) stimulation without causing a common tingling side effect called paresthesia. Experts say Nevro's Senza SCS system represents a significant advance in SCS technology, and it is the only system to be FDA approved with superiority labeling.

HF10 Therapy Labeled as Superior to Traditional SCS Therapy for Chronic Back and Leg Pain  
Providing innovative evidence-based solutions for the treatment of chronic pain, announced that it has received approval from the United States Food and Drug Administration (FDA) for its Senza spinal cord stimulation (SCS) system.

The Senza SCS system, which delivers Nevro's proprietary HF10 therapy, is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.

The Senza system was the subject of the SENZA-RCT pivotal study, a ground-breaking study that was the first to directly compare SCS therapies. The multicenter study was conducted across 11 U.S. clinical trial sites, comparing the safety and effectiveness of HF10 therapy to traditional SCS therapy. The study enrolled 241 patients, making it the largest prospective randomized SCS study ever conducted to assess the treatment of chronic back and leg pain.

"The Nevro organization is prepared to initiate a responsible rollout of HF10 therapy to the U.S. pain management community and the patients they serve to ensure we deliver the clinical outcomes that are the foundation of our therapy and company."

Touchstone will be the first in the State of Oregon by Dr Shawn Sills. This new technology looks very promising for chronic pain patients.

For media inquiries please contact:  
Rick Coimbra at Touchstone: [rickc@touchstonepain.com](mailto:rickc@touchstonepain.com) or 541-773-1435